|December 14, 2018 3:13 p.m.|
Motif Bio is a clinical stage biopharmaceutical company developing novel antibiotics to treat patients with serious and life-threatening infections caused by multi-drug resistant bacteria.
|Motif Bio to participate at upcoming Jefferies London Healthcare Conference|
October 31, 2018
|Motif Bio Presents New Iclaprim Data at IDWeek|
October 3, 2018
|Motif Bio Reports Half-Year 2018 Financial Results and Operational Progress|
September 25, 2018